JP2018538248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538248A5 JP2018538248A5 JP2018521294A JP2018521294A JP2018538248A5 JP 2018538248 A5 JP2018538248 A5 JP 2018538248A5 JP 2018521294 A JP2018521294 A JP 2018521294A JP 2018521294 A JP2018521294 A JP 2018521294A JP 2018538248 A5 JP2018538248 A5 JP 2018538248A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound according
- pharmaceutically acceptable
- ring
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Chemical group 0.000 description 8
- 229920006395 saturated elastomer Chemical group 0.000 description 8
- 229910052717 sulfur Chemical group 0.000 description 8
- 239000011593 sulfur Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 5
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- -1 n-butylenyl Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020195185A JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2024032219A JP2024073492A (ja) | 2015-10-23 | 2024-03-04 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2025139729A JP2025176049A (ja) | 2015-10-23 | 2025-08-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245553P | 2015-10-23 | 2015-10-23 | |
| US62/245,553 | 2015-10-23 | ||
| US201662336219P | 2016-05-13 | 2016-05-13 | |
| US62/336,219 | 2016-05-13 | ||
| PCT/US2016/058188 WO2017070518A1 (en) | 2015-10-23 | 2016-10-21 | Modulators of sestrin-gator2 interaction and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195185A Division JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538248A JP2018538248A (ja) | 2018-12-27 |
| JP2018538248A5 true JP2018538248A5 (enExample) | 2019-11-28 |
| JP6800968B2 JP6800968B2 (ja) | 2020-12-16 |
Family
ID=58557891
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521294A Active JP6800968B2 (ja) | 2015-10-23 | 2016-10-21 | セストリン−ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2020195185A Active JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2024032219A Withdrawn JP2024073492A (ja) | 2015-10-23 | 2024-03-04 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2025139729A Pending JP2025176049A (ja) | 2015-10-23 | 2025-08-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195185A Active JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2024032219A Withdrawn JP2024073492A (ja) | 2015-10-23 | 2024-03-04 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2025139729A Pending JP2025176049A (ja) | 2015-10-23 | 2025-08-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10100066B2 (enExample) |
| EP (2) | EP3364958B1 (enExample) |
| JP (4) | JP6800968B2 (enExample) |
| KR (2) | KR102708250B1 (enExample) |
| CN (2) | CN121102186A (enExample) |
| AU (4) | AU2016342027B2 (enExample) |
| BR (1) | BR122021005850B1 (enExample) |
| CA (2) | CA3234750A1 (enExample) |
| CO (1) | CO2018005315A2 (enExample) |
| DK (1) | DK3364958T3 (enExample) |
| ES (1) | ES2941969T3 (enExample) |
| FI (1) | FI3364958T3 (enExample) |
| HR (1) | HRP20230331T1 (enExample) |
| HU (1) | HUE061437T2 (enExample) |
| IL (1) | IL258779B (enExample) |
| LT (1) | LT3364958T (enExample) |
| MX (2) | MX389001B (enExample) |
| PL (1) | PL3364958T3 (enExample) |
| PT (1) | PT3364958T (enExample) |
| RS (1) | RS64114B1 (enExample) |
| SG (1) | SG11201803099SA (enExample) |
| SI (1) | SI3364958T1 (enExample) |
| WO (1) | WO2017070518A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| HRP20230331T1 (hr) | 2015-10-23 | 2023-07-07 | Navitor Pharmaceuticals, Inc. | Modulatori interakcije sestrin-gator2 i njihova uporaba |
| JP7179015B2 (ja) * | 2017-04-26 | 2022-11-28 | ナビター ファーマシューティカルズ， インコーポレイテッド | Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用 |
| US11345654B2 (en) * | 2018-10-24 | 2022-05-31 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| WO2020092383A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP3873900B1 (en) | 2018-10-30 | 2025-01-08 | Gilead Sciences, Inc. | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| PL3873605T3 (pl) | 2018-10-30 | 2025-03-03 | Gilead Sciences, Inc. | Związki hamujące integrynę alfa4beta7 |
| PT3873884T (pt) | 2018-10-30 | 2025-02-25 | Gilead Sciences Inc | Derivados de 3-(quinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidina-2,4-diona como inibidores da integrina alfa4beta7 para o tratamento de doenças inflamatórias |
| CN111689993B (zh) * | 2019-03-11 | 2023-04-14 | 凯特立斯（深圳）科技有限公司 | 一种新的含硼类佐米药物关键中间体手性α-氨基硼酸酯的制备方法 |
| EP4013499A1 (en) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| CN114786660A (zh) * | 2019-11-01 | 2022-07-22 | 纳维托制药有限公司 | 使用mtorc1调节剂的治疗方法 |
| CN112699498B (zh) * | 2021-03-23 | 2021-05-25 | 中国空气动力研究与发展中心计算空气动力研究所 | 基于归一化物理量间断特征的喷流模拟激波快速判别方法 |
| EP4234014A1 (en) * | 2022-02-28 | 2023-08-30 | Insusense ApS | Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases |
| KR102777583B1 (ko) | 2024-05-24 | 2025-03-07 | 충남대학교산학협력단 | 세스트린2를 포함하는 전립선 질환 예방 또는 치료용 조성물 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452015A (en) * | 1967-07-12 | 1969-06-24 | Lilly Co Eli | Synthesis of beta,beta-alkyl pyrrolidines |
| US3567726A (en) * | 1968-12-18 | 1971-03-02 | Lilly Co Eli | Synthesis of beta,beta-di-alkyl pyrrolidines |
| US4110368A (en) | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
| US4179574A (en) * | 1973-04-27 | 1979-12-18 | American Cyanamid Company | Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclo-pentenones |
| US4346110A (en) | 1981-06-01 | 1982-08-24 | Merrell Toraude Et Compagnie | Method for treating depression |
| JPS61149964A (ja) | 1984-12-25 | 1986-07-08 | Canon Inc | 電子写真感光体 |
| US4670196A (en) | 1985-09-05 | 1987-06-02 | Norton Company | Tower packing element |
| EP0232776B1 (en) | 1986-01-24 | 1990-10-24 | Toray Industries, Inc. | 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi2 derivatives |
| GB8827885D0 (en) | 1988-11-30 | 1989-01-05 | Wellcome Found | Novel heterocyclic pesticidal compounds |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| DE19623142A1 (de) * | 1996-06-10 | 1997-12-11 | Huels Chemische Werke Ag | Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung |
| PL331854A1 (en) | 1996-08-28 | 1999-08-16 | Procter & Gamble | Phosphinamides as inhibitors of metaloprotease matrix |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| AU3459999A (en) * | 1998-04-27 | 1999-11-16 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
| IL136761A0 (en) | 1998-11-04 | 2001-06-14 | Montell Technology Company Bv | Components and catalysts for the polymerization of olefins |
| US6329546B1 (en) | 1999-01-12 | 2001-12-11 | Laboratory Of Molecular Biophotonics | Caged amino acids |
| US20030203900A1 (en) * | 1999-05-18 | 2003-10-30 | Martin Quibell | Cysteine protease inhibitors |
| ES2317839T3 (es) * | 1999-06-10 | 2009-05-01 | Warner-Lambert Company Llc | Acidos 3-propil gamma-aminobutiricos monosustituidos. |
| AU777911B2 (en) | 1999-12-10 | 2004-11-04 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| US7300775B2 (en) * | 1999-12-29 | 2007-11-27 | Verenium Corporation | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP5076257B2 (ja) * | 2001-02-01 | 2012-11-21 | 旭硝子株式会社 | 撥水性組成物、表面処理された基材、その製造方法および輸送機器用物品 |
| US7071189B2 (en) | 2001-04-27 | 2006-07-04 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ATE419865T1 (de) | 2002-08-14 | 2009-01-15 | Silence Therapeutics Ag | Verwendung von protein-kinase-n-beta |
| US6787664B2 (en) * | 2002-09-17 | 2004-09-07 | Warner-Lambert Company Llc | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| NZ542475A (en) | 2003-04-03 | 2009-04-30 | Semafore Pharmaceuticals Inc | PI-3 kinase inhibitor prodrugs |
| NZ543897A (en) | 2003-05-30 | 2009-04-30 | Gemin X Pharmaceuticals Canada | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| US20070212428A1 (en) | 2004-06-04 | 2007-09-13 | Mood Management Sciences, Inc. | Methods and compositions for treating mood disorder |
| DE102004053407A1 (de) * | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Acylierte Nonadepsipeptide II |
| PL1856135T3 (pl) | 2005-01-19 | 2010-05-31 | Rigel Pharmaceuticals Inc | Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie |
| CA2598491A1 (en) * | 2005-02-18 | 2006-11-09 | Innodia Inc. | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| RS55634B1 (sr) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| ES2347187T3 (es) | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
| CA2661220A1 (en) | 2006-08-21 | 2008-02-28 | James R. Hauske | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| SI2529622T1 (en) | 2006-09-22 | 2018-06-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| KR20130095850A (ko) | 2006-09-25 | 2013-08-28 | 욱크하르트 리미티드 | 치환된 피페리디노페닐 옥사졸리디논 |
| TWI397418B (zh) | 2006-10-10 | 2013-06-01 | Otsuka Pharma Co Ltd | 抗憂鬱劑 |
| EP2091937A2 (en) | 2006-10-20 | 2009-08-26 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| WO2008109943A1 (en) | 2007-03-12 | 2008-09-18 | Cytopia Research Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| US8445686B2 (en) * | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| EA017218B1 (ru) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak-киназ |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010044885A2 (en) | 2008-10-17 | 2010-04-22 | Whitehead Institute For Biomedical Research | Soluble mtor complexes and modulators thereof |
| EP2443128B1 (en) * | 2009-06-19 | 2017-12-20 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of alpha-amino boronic esters |
| EP2459182B1 (en) | 2009-07-30 | 2017-09-06 | University of Zürich | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| EA201201052A1 (ru) * | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
| BR112012033770A2 (pt) | 2010-06-30 | 2016-11-22 | Fujifilm Corp | novo derivado de nicotinamida ou sal do mesmo |
| CN102464701B (zh) * | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| CA2820109C (en) * | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| WO2013142229A1 (en) * | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| EP3202397B1 (en) | 2012-08-06 | 2019-09-25 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
| WO2014127052A1 (en) * | 2013-02-13 | 2014-08-21 | Zondlo Neal | Perfluoro-tert-butyl hydroxyproline |
| ES2885424T3 (es) | 2013-03-15 | 2021-12-13 | Knopp Biosciences Llc | Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7 |
| US20160129030A1 (en) | 2013-06-14 | 2016-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| EP3191116B1 (en) | 2014-09-12 | 2020-11-25 | The Whitehead Institute for Biomedical Research | Methods of identifying modulators of sestrin-gator2 interaction and use of same to modulate mtorc1 |
| HRP20230331T1 (hr) | 2015-10-23 | 2023-07-07 | Navitor Pharmaceuticals, Inc. | Modulatori interakcije sestrin-gator2 i njihova uporaba |
| US20180327364A1 (en) | 2015-11-13 | 2018-11-15 | Brandeis University | Mtor inhibitors and methods of use thereof |
| WO2017185010A1 (en) | 2016-04-21 | 2017-10-26 | Beyond Batten Disease Foundation | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| JP7179015B2 (ja) | 2017-04-26 | 2022-11-28 | ナビター ファーマシューティカルズ， インコーポレイテッド | Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用 |
| KR20240154700A (ko) | 2018-02-08 | 2024-10-25 | 오비드 테라퓨틱스 인크. | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| US11345654B2 (en) | 2018-10-24 | 2022-05-31 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US10926803B2 (en) | 2019-07-17 | 2021-02-23 | GM Global Technology Operations LLC | Four rail front crush structure with load dissemination into eight element support structure |
| JP6689441B1 (ja) | 2019-11-01 | 2020-04-28 | エヌ・ティ・ティ・コミュニケーションズ株式会社 | 電子マネー管理システムおよび電子マネー管理方法 |
| CN114786660A (zh) | 2019-11-01 | 2022-07-22 | 纳维托制药有限公司 | 使用mtorc1调节剂的治疗方法 |
-
2016
- 2016-10-21 HR HRP20230331TT patent/HRP20230331T1/hr unknown
- 2016-10-21 US US15/331,362 patent/US10100066B2/en active Active
- 2016-10-21 CN CN202511264584.8A patent/CN121102186A/zh active Pending
- 2016-10-21 CA CA3234750A patent/CA3234750A1/en active Pending
- 2016-10-21 SG SG11201803099SA patent/SG11201803099SA/en unknown
- 2016-10-21 KR KR1020187011517A patent/KR102708250B1/ko active Active
- 2016-10-21 HU HUE16858326A patent/HUE061437T2/hu unknown
- 2016-10-21 JP JP2018521294A patent/JP6800968B2/ja active Active
- 2016-10-21 SI SI201631682T patent/SI3364958T1/sl unknown
- 2016-10-21 KR KR1020247030702A patent/KR20240144424A/ko active Pending
- 2016-10-21 EP EP16858326.8A patent/EP3364958B1/en active Active
- 2016-10-21 AU AU2016342027A patent/AU2016342027B2/en active Active
- 2016-10-21 PL PL16858326.8T patent/PL3364958T3/pl unknown
- 2016-10-21 DK DK16858326.8T patent/DK3364958T3/da active
- 2016-10-21 LT LTEPPCT/US2016/058188T patent/LT3364958T/lt unknown
- 2016-10-21 CN CN201680069916.XA patent/CN108289866B/zh active Active
- 2016-10-21 MX MX2018004674A patent/MX389001B/es unknown
- 2016-10-21 ES ES16858326T patent/ES2941969T3/es active Active
- 2016-10-21 BR BR122021005850-4A patent/BR122021005850B1/pt active IP Right Grant
- 2016-10-21 RS RS20230265A patent/RS64114B1/sr unknown
- 2016-10-21 PT PT168583268T patent/PT3364958T/pt unknown
- 2016-10-21 FI FIEP16858326.8T patent/FI3364958T3/fi active
- 2016-10-21 CA CA3001703A patent/CA3001703C/en active Active
- 2016-10-21 EP EP22186093.5A patent/EP4112611A3/en active Pending
- 2016-10-21 WO PCT/US2016/058188 patent/WO2017070518A1/en not_active Ceased
-
2018
- 2018-04-16 MX MX2022000053A patent/MX2022000053A/es unknown
- 2018-04-17 IL IL258779A patent/IL258779B/en unknown
- 2018-05-09 US US15/974,734 patent/US10414782B2/en active Active
- 2018-05-21 CO CONC2018/0005315A patent/CO2018005315A2/es unknown
-
2019
- 2019-07-18 US US16/515,788 patent/US10752644B2/en active Active
-
2020
- 2020-07-29 US US16/941,821 patent/US11325924B2/en active Active
- 2020-11-25 JP JP2020195185A patent/JP7449843B2/ja active Active
-
2021
- 2021-08-11 AU AU2021215177A patent/AU2021215177B2/en active Active
-
2022
- 2022-03-25 US US17/704,892 patent/US12378263B2/en active Active
-
2023
- 2023-12-12 AU AU2023282205A patent/AU2023282205A1/en not_active Abandoned
-
2024
- 2024-03-04 JP JP2024032219A patent/JP2024073492A/ja not_active Withdrawn
-
2025
- 2025-08-25 JP JP2025139729A patent/JP2025176049A/ja active Pending
- 2025-10-14 AU AU2025252521A patent/AU2025252521A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538248A5 (enExample) | ||
| JP2020517707A5 (enExample) | ||
| JP6657182B2 (ja) | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 | |
| JP2018522879A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2010528021A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| RU2016152470A (ru) | Применение замещенных оксадиазолов для борьбы с фитопатогенными грибами | |
| JP2020503249A5 (enExample) | ||
| JP2017536369A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| JP2018524333A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2015509110A5 (enExample) | ||
| RU2017144495A (ru) | Противогельминтные депсипептидные соединения | |
| JP2016534059A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2013505946A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2019510794A5 (enExample) |